# | Title | Journal | Year | Citations |
---|
1 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 7,261 |
2 | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma | New England Journal of Medicine | 2017 | 3,865 |
3 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 3,077 |
4 | Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer | New England Journal of Medicine | 2012 | 2,474 |
5 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | New England Journal of Medicine | 2018 | 2,150 |
6 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Nature | 2014 | 2,109 |
7 | Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia | New England Journal of Medicine | 2013 | 2,019 |
8 | Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer | New England Journal of Medicine | 2020 | 1,513 |
9 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial | Lancet Oncology, The | 2019 | 1,467 |
10 | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature | 2019 | 1,375 |
11 | Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma | New England Journal of Medicine | 2012 | 1,201 |
12 | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia | Blood | 2017 | 1,173 |
13 | Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 1,133 |
14 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma | New England Journal of Medicine | 2021 | 1,129 |
15 | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma | Cancer Discovery | 2018 | 1,108 |
16 | KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma | New England Journal of Medicine | 2020 | 1,067 |
17 | Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2015 | 1,035 |
18 | PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma | New England Journal of Medicine | 2018 | 997 |
19 | PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma | New England Journal of Medicine | 2014 | 956 |
20 | Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study | Lancet, The | 2011 | 938 |
21 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma | Nature Medicine | 2018 | 900 |
22 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial | Lancet, The | 2012 | 856 |
23 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer | Journal of Clinical Oncology | 2016 | 755 |
24 | Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma | JAMA Oncology | 2017 | 750 |
25 | Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial | Lancet, The | 2016 | 724 |
26 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study | Lancet, The | 2021 | 711 |
27 | Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial | Leukemia | 2016 | 685 |
28 | Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy | Journal of Clinical Oncology | 2011 | 647 |
29 | Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors | Journal of Clinical Oncology | 2012 | 635 |
30 | Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study | Journal of Clinical Oncology | 2018 | 584 |
31 | Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study | Breast Cancer Research and Treatment | 2018 | 564 |
32 | Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia | Blood | 2014 | 562 |
33 | Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma | Nature Communications | 2016 | 550 |
34 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer | Annals of Oncology | 2018 | 526 |
35 | Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study | Journal of Clinical Oncology | 2016 | 517 |
36 | MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer | Clinical Cancer Research | 2017 | 492 |
37 | Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial | Lancet Oncology, The | 2012 | 487 |
38 | Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial | Lancet Oncology, The | 2012 | 479 |
39 | CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer | Journal of Clinical Oncology | 2018 | 459 |
40 | Efficacy of Selpercatinib in RET-Altered Thyroid Cancers | New England Journal of Medicine | 2020 | 454 |
41 | Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 453 |
42 | Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2013 | 451 |
43 | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 | Annals of Oncology | 2014 | 446 |
44 | Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial | Lancet Oncology, The | 2011 | 444 |
45 | Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study | Lancet Oncology, The | 2017 | 412 |
46 | Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma | Blood | 2012 | 396 |
47 | Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up | Leukemia | 2012 | 395 |
48 | Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial | Lancet, The | 2020 | 393 |
49 | Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial | Journal of Clinical Oncology | 2015 | 392 |
50 | Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study | Journal of Clinical Oncology | 2017 | 384 |